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Abstract 
Background: Concerns about potential adverse effects of long‑term exposure to lithium as a mood‑stabilizing treat‑
ment notably include altered renal function. However, the incidence of severe renal dysfunction; rate of decline over 
time; effects of lithium dose, serum concentration, and duration of treatment; relative effects of lithium exposure vs. 
aging; and contributions of sex and other factors all remain unclear.
Methods: Accordingly, we acquired data from 12 collaborating international sites and 312 bipolar disorder patients 
(6142 person‑years, 2669 assays) treated with lithium carbonate for 8–48 (mean 18) years and aged 20–89 (mean 56) 
years. We evaluated changes of estimated glomerular filtration rate (eGFR) as well as serum creatinine, urea–nitrogen, 
and glucose concentrations, white blood cell count, and body‑mass index, and tested associations of eGFR with 
selected factors, using standard bivariate contrasts and regression modeling.
Results: Overall, 29.5% of subjects experienced at least one low value of eGFR (<60 mL/min/1.73 m2), most 
after ≥15 years of treatment and age > 55; risk of ≥2 low values was 18.1%; none experienced end‑stage renal failure. 
eGFR declined by 0.71%/year of age and 0.92%/year of treatment, both by 19% more among women than men. Mean 
serum creatinine increased from 0.87 to 1.17 mg/dL, BUN from 23.7 to 33.1 mg/dL, glucose from 88 to 122 mg/dL, and 
BMI from 25.9 to 26.6 kg/m2. By multivariate regression, risk factors for declining eGFR ranked: longer lithium treat‑
ment, lower lithium dose, higher serum lithium concentration, older age, and medical comorbidity. Later low eGFR 
was also predicted by lower initial eGFR, and starting lithium at age ≥ 40 years.
Limitations: Control data for age‑matched subjects not exposed to lithium were lacking.
Conclusions: Long‑term lithium treatment was associated with gradual decline of renal functioning (eGFR) by about 
30% more than that was associated with aging alone. Risk of subnormal eGFR was from 18.1% (≥2 low values) to 
29.5% (≥1 low value), requiring about 30 years of exposure. Additional risk factors for low eGFR were higher serum 
lithium level, longer lithium treatment, lower initial eGFR, and medical comorbidity, as well as older age.
Keywords: Blood urea nitrogen, Body‑mass index, Creatinine, eGFR, Glomerular filtration rate, Glucose, Lithium, 
Staging of renal function, White blood cell count
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Background
Decades of widespread international clinical use of 
lithium salts with controlled dosing, as well as exten-
sive therapeutic research, support the value of lithium 
as a cornerstone of long-term, prophylactic treatment 
of patients diagnosed with bipolar disorder (Bauer et al. 
2006; Baldessarini 2013; Severus et  al. 2014; Bauer and 
Gitlin 2016). Nevertheless, an adverse effect of major 
concern associated with long-term lithium treatment is 
the risk of developing chronic kidney disease (CKD). This 
outcome usually is defined as a decrease of glomerular 
filtration rate (GFR) to <60 mL/min per 1.73 m2 observed 
at least twice in not less than 3 months (Azab et al. 2015). 
Severe loss of renal function and end-stage renal disease 
(ESRD) are uncommon with lithium treatment, with a 
prevalence of approximately 1.5%, but 7-folds higher than 
the general population (Aiff et al. 2015). Risk of renal dys-
function is believed to be associated with longer exposure 
to lithium as well as with advancing age with or with-
out lithium, and appears to have changed little over the 
recent decades (Aiff et  al. 2015; Jonczyk-Potoczna et  al. 
2016). Pathological renal changes associated with long 
exposure to lithium in clinical doses have included the 
presence of macrocysts, microcysts, glomerulosclerosis, 
proximal tubular atrophy, and chronic interstitial fibro-
sis (Albrecht et al. 1980; Oliveira et al. 2010; Alsady et al. 
2016; Jonczyk-Potoczna et  al. 2016). Molecular mecha-
nisms associated with such dysfunction appear to be 
multiple and complex. Based mainly on preclinical mod-
els, they include alterations in calcium signaling, inosi-
tol monophosphate and phosphodiesterase activities, 
prostaglandins, sodium-solute transport, G-protein-cou-
pled receptors, nitric oxide, vasopressin aquaporin, and 
inflammation pathways (Rej et  al. 2016). However, it is 
unclear why only some patients develop nephropathy in 
association with lithium treatment, regardless of age or 
lithium exposure.
At least 20 findings related to renal dysfunction have 
emerged from studies of patients treated long term with 
lithium (Azab et al. 2015). They include (Table 1) (a) sig-
nificant increase of serum creatinine concentration, not 
associated with age, in 99 lithium-treated patients fol-
lowed for up to 10  years (Depaulo et  al. 1981); (b) no 
difference in eGFR among 30 patients aged 55, treated 
with lithium for 6.2 years and 30 others not exposed to 
lithium (Hullin et  al. 1979); (c) no difference in eGFR 
among 32 patients aged 49 years, treated with lithium for 
5.7 years and 32 matched controls (Bendz 1985); (d) more 
Table 1 Reports on renal effects of lithium treatment
Abnormal renal functioning was associated with longer exposure to lithium in these studies (15.3 ± 9.54 vs. 5.00 ± 0.91 years, respectively [t = 2.37, p = 0.035])
Report Subjects (n) Age (years) Lithium exposure (years) Main findings
Li No Li
Hullin et al. (1979) 30 30 55 6.2 No difference in eGFR
Depaulo et al. (1981) 99 0 41 2.8 Creatinine increased with Li
Bendz (1985) 32 32 49 5.7 No difference in eGFR
Bendz et al. (1996) 13 13 59 18.0 eGFR fell with Li
Coşkunol et al. (1997) 107 29 39 4.5 No difference in eGFR
Turan et al. (2002) 10 10 35 1.3 and 6.7 eGFR fell with long‑term Li
Bendz et al. (2010) 3369 Genl. pop. 65 23.0 ESRD 6.5‑fold more often with Li
Rybakowski et al. (2012) 80 0 60 16.0 eGFR < 60: 22.5%; 2.4‑times more in men
Bocchetta et al. (2013) 139 70 54 >1.0 eGFR < 60: 4.8‑fold more often with Li
Minay et al. (2013) 330 659 48 – eGFR < 60: similar with/without Li
Aiff et al. (2014) 1995 0 66 27.0 ESRD 7.8‑fold more often with Li
Aprahamian et al. (2014) 32 27 74 4.0 No difference in renal function
Close et al. (2014) 2496 3864 49 – eGFR < 60: 3.25‑times less with Li
Aiff et al. (2015) 630 0 66 ≥10.0 eGFR < 60: 32%; ESRD: 4.5‑fold more with Li
Bocchetta et al. (2015) 1953 0 – 10 and 25 eGFR < 50: 12% in 10, 50% in 25 yrs of Li
Clos et al. (2015) 305 815 43 4.6 No difference in eGFR
Shine et al. (2015) 4678 689,228 52 ≤28.0 eGFR < 60: 1.21‑fold more often with Li
Castro et al. (2016) 3850 0 54 1.4 eGFR < 60: 25.7% lower with multiple doses/day
Hayes et al. (2016) 2148 4523 46 18 eGFR < 60: ~twofold higher HR with Li
Kessing et al. (2015) Natl. sample 0 – – Clinical CKD 3.6‑times more with Li
N = 20 studies >22,296 >699,300 53.1 ± 10.5 10.9 ± 8.9 Function decreased in 15/20 reports (75.0%)
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prevalent low eGFR in 13 patients (mean age, 59  years) 
treated with lithium for 18  years (5/13) than that in 
13 matched controls never exposed to lithium (0/13; 
χ2 = 6.19, p = 0.01) (Bendz et al. 1996); (e) no difference 
in eGFR in 107 patients aged 39 treated with lithium for 
4.5 years (eGFR = 86.5 [CI 82.4–90.6]) compared with 29 
matched controls (83.9 [76.1–91.7] units) (Coşkunol et al. 
1997); (f ) lower eGFR among 10 patients/group of aver-
age age 35, exposed to lithium for 6.7 years (72.8 [50.7–
94.9]) compared to those exposed for 1.3  years (150 
[129–172]) or no exposure (125 [112–138] units) (Turan 
et al. 2002); (g) a risk of ESRD of 0.53% among 3369 sub-
jects of average age 65 exposed to lithium for 23  years, 
compared to 0.082% of the general Swedish population—
a 6.5-fold difference (χ2 = 82.5, p < 0.0001) (Bendz et al. 
2010); (h) eGFR < 60 units in 23.0% of 80 patients treated 
with lithium up to 38 (mean, 17) years, and more often 
among men (38%) than women (16%; p  =  0.04) (Ryba-
kowski et al. 2012); (i) eGFR values were lower in 27.3% 
of 139 lithium-treated patients of mean age 54, exposed 
to lithium for  ≥1  year, compared to 5.71% among 70 
psychiatric controls—a difference of 4.8-fold (χ2 =  9.66, 
p  <  0.002), and were more likely among older patients 
and men (Bocchetta et  al. 2013); (j) mean GFR 8.0% 
lower among 330 general practice patients taking lith-
ium compared with 659 matched controls, with simi-
lar prevalence of eGFR values ≤60 units in both groups 
(17.0 vs. 13.1%; χ2 = 2.75, p = 0.10) (Minay et al. 2013); 
(k) the rate of dialysis treatment or renal transplantation 
in the Swedish general population was 0.019%, compared 
to a 7.8-fold higher rate of 1.5% among 1995 lithium-
treated patients of age 66 years given lithium for 27 years 
(χ2 = 176, p < 0.0001) (Aiff et al. 2014); (l) no difference 
in renal function in a 2-year randomized control trial 
(RCT) for patients given lithium  >4  years (Aprahamian 
et al. 2014); (m) eGFR < 60 units in 12.3% of 2496 general 
practice patients given lithium for undefined times, com-
pared to a 3.25-fold lower risk of 3.78% in 3864 bipolar 
disorder patients not given lithium, all of average age 49 
(χ2 =  165, p  <  0.0001) (Close et  al. 2014); (n) values of 
eGFR < 60 units were encountered in 32% of 630 subjects 
aged 66  years treated with lithium ≥10  years, and 4.5% 
developed ESRD (stage 4 or 5; eGFR < 30 units), with lit-
tle sex-difference in either outcome (Aiff et al. 2015), (o) 
eGFR < 60 units was found in 12% of 953 patients given 
lithium for 10  years and in 50% by 25  years (Bocchetta 
et  al. 2015); (p) no significant difference in the annual 
decline of eGFR in a case–control study: 305 patients 
aged 43 given lithium for an average of 4.6  years and 
815 controls given other treatments (1.3 vs. 0.9 units) 
after adjustment for age, baseline eGFR, comorbidities, 
exposure to nephrotoxic drugs, and episodes of acute 
lithium toxicity (Clos et  al. 2015); (q) eGFR  <  60 units 
was 1.21-times more prevalent among 4678 lithium-
treated subjects than among 689,228 controls of mean 
age 52 treated for up to 28  years, after adjustment for 
age, sex, and diabetes (estimates: 62.3 vs. 51.4%; χ2 = 118, 
p < 0.0001) (Shine et al. 2015); (r) risk for eGFR < 60 units 
among 3850 patients, aged 54 years, treated with lithium 
for an average of 1.4  years was 25.7%, and was higher 
with multiple daily doses, higher serum concentrations, 
and co-treatment with first-generation neuroleptics 
(Castro et al. 2016); [s] eGFR < 60 units was about two-
fold more prevalent among 2148 lithium-treated patients 
than among those treated with valproate (n  =  1670), 
olanzapine (n = 1477), or quetiapine (n = 1376) (Hayes 
et  al. 2016); (t) in a nationwide population study, clini-
cally diagnosed CKD was increased by up to 3.6-fold 
with longer exposure to lithium, and associated with use 
of anticonvulsants (with risk of confounding by selective 
avoidance of lithium with renal failure), but not antide-
pressants or antipsychotics (Kessing et al. 2015). To sum-
marize, all these studies point out that lower eGFR is 
associated with older age and longer exposure to lithium 
(Table 1).
In addition to changes in renal functioning, the pres-
ence of macrocysts or microcysts as possible precursors 
of loss of kidney function has been reported in sev-
eral renal-imaging studies following long-term lithium 
treatment (Tuazon et  al. 2008; Slaughter et  al. 2010; 
Farshchian et  al. 2013; Karaosmanoglu et  al. 2013; Jon-
czyk-Potoczna et  al. 2016). Also, an increase of renal 
neoplasia during long-term treatment with lithium has 
been suggested (Zaidan et al. 2014), but not supported by 
other observations (Baldessarini and Tondo 2014; Licht 
et al. 2014; Pottegård et al. 2016).
To extend the preceding findings, we evaluated effects 
of lithium on GFR and other metabolic parameters in a 
composite sample of 312 bipolar disorder patients fol-
lowed for 8–48  years in 12 international specialized 
mood-disorder clinics with extensive experience in the 
clinical use of lithium.
Methods
This international collaborative study involved data pro-
vided by 12 sites in Argentina, Canada, Germany, Italy, 
Poland, Spain, and Switzerland (Table  2). Subjects were 
adults meeting DSM-IV diagnostic criteria for bipo-
lar I or II disorder. Participation was based on meeting 
local institutional requirements for the ethical conduct 
of research. Measurements considered included age; 
sex; years of exposure to lithium treatment; mean daily 
dose of lithium carbonate and mean daily trough serum 
concentration of lithium; body-mass index (BMI), white 
blood cell counts (WBC), and assays of serum concen-
trations of glucose, blood urea nitrogen (BUN), and 
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creatinine, with estimated GFR (eGFR, in units of mL/
min/1.73  m2) computed according to the chronic kid-
ney disease (CKD)-epidemiology collaboration (CKD-
EPI) formulas for Caucasian (as all study subjects were) 
women and men (Levey et al. 2009):
Metabolic measures at baseline were compared over 
times of exposure to lithium treatment, ranging from 8 to 
48  years, using ANOVA methods (t-scores). Additional 
analyses focused on the prevalence of renal dysfunction 
based on low eGFR (<60  mL/min/1.73  m2), and con-
sidered standard functional staging, as: Stage 1 normal 
functioning (GFR ≥  90); Stage 2 mildly decreased func-
tioning (GFR  =  60–89); Stage 3 moderate dysfunction 
(GFR = 30–59); Stage 4 severe dysfunction (GFR = 15–
29); and Stage 5 kidney failure (GFR < 15 or needing dialy-
sis) (American National Kidney Foundation, NKF 2002, 
2014). Low eGFR included Stages 3 and 4.
We addressed the prevalence of low values of eGFR across 
study sites, and changes with time and in association with 
selected measures, including ages (at onset, at lithium start 
and at the last follow up visit), sex, co-occurring medical ill-
nesses, and exposure to lithium (by daily dose, mean serum 
concentration, and time) as well as to other psychotropic 
drugs (anticonvulsants, antidepressants, antipsychotics). 
Associations of potential risk factors were tested by com-
paring subjects meeting the criterion of at least one low 
females : 141× ([creatinine]/0.7)−0.329
× ([creatinine]/0.7)−1.209 × 0.993age × 1.018;
males : 141× ([creatinine]/0.9)−0.411
× ([creatinine]/0.9)−1.209 × 0.993age × 1.018.
value of eGFR (<60 units) or not, in bivariate comparisons 
using ANOVA methods (t-scores) for continuous meas-
ures and contingency tables (χ2) for categorical measures, 
followed by multivariable logistic regression modeling. In 
order to differentiate effects on eGFR of age and lithium 
exposure, we also sampled subjects matched for long-term 
lithium exposure (20–25  years), but starting treatment at 
ages <40 vs. ≥40 years. Data are shown as mean ± standard 
deviation (SD) or with 95% confidence interval (CI), unless 
stated otherwise. Analyses employed commercial software: 
Statview.5 (SAS Institute, Cary, NC, USA; for spreadsheets), 
and Stata.12 (StataCorp, College Station, TX, USA).
Results
Subject characteristics
The pooled study sample consisted of 312 adult, bipo-
lar disorder subjects, treated with lithium carbon-
ate for 8–48 (mean 17.9 ±  8.62) years (with or without 
other treatments), representing a total exposure of 6142 
person-years. Selected characteristics of subjects from 
each site (subject count, age at entry to study site, age 
at last contact, and years treated with lithium) are sum-
marized in Table 2. The proportion of women/men was 
57.7/42.3%; age at study site intake averaged 37.9 ± 12.9 
(range 11–76) years, and last age averaged 55.8  ±  14.2 
(range 20–89) years. Diagnoses were 78.2% bipolar I and 
21.8% bipolar II, with an average age at illness-onset of 
28.5 ± 11.1 years.
Metabolic parameters at baseline and during lithium 
treatment
Summary data for average measures and their status 
across years of treatment with lithium are based on 2669 
assays (Table  3). They include: lithium carbonate dose 
Table 2 Subject age and lithium exposure across study sites
Total exposure = 6142 person-years
Across the 12 sites, among 312 subjects: at = 1.55, p = 0.007; bt = 1.70, p = 0.001; ct = 1.13, p = 0.24
Study site Subjects (n) Intake  agea Final  ageb Years on  Lic
Barcelona: University of Barcelona 26 32.3 ± 8.06 51.8 ± 11.4 19.4 ± 7.41
Berlin: Charité Medical Center 30 39.5 ± 12.4 56.6 ± 14.9 17.2 ± 8.12
Buenos Aires: Palermo University 9 47.2 ± 12.0 62.3 ± 13.4 15.1 ± 5.93
Cagliari: Lucio Bini Mood Disorder Center 50 38.1 ± 12.1 54.6 ± 14.5 17.5 ± 8.61
Cagliari: University of Cagliari 30 37.1 ± 11.2 62.2 ± 13.1 24.1 ± 8.86
Dresden: University of Dresden 22 33.5 ± 12.7 53.8 ± 13.2 20.3 ± 9.49
Halifax: Dalhousie University 27 43.5 ± 13.7 55.4 ± 13.7 11.9 ± 3.97
Lugano: Viarnetto Clinic 21 33.8 ± 11.6 52.0 ± 12.9 18.2 ± 9.45
Pisa: University of Pisa 25 37.6 ± 13.1 49.4 ± 13.8 11.7 ± 6.29
Poznan: University of Poznan 20 43.1 ± 14.2 66.2 ± 10.7 23.1 ± 8.59
Rome: Lucio Bini Mood Disorder Center 46 36.8 ± 15.6 54.6 ± 15.9 18.4 ± 9.47
Würzburg: University of Würzburg 6 45.0 ± 14.9 61.8 ± 9.75 6.80 ± 7.94
Total [95% CI] 312 37.9 [37.5–39.3] 55.8 [54.2–57.4] 17.9 [16.9–18.9]
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(833  ±  311  mg/day), mean daily trough serum concen-
trations of lithium (0.656  ±  0.184  mEq/L), body-mass 
index (BMI, 27.0 ±  4.86  kg/m2), serum glucose concen-
tration (97.3 ±  28.4  mg/dL), blood urea nitrogen (BUN, 
26.1  ±  12.9  mg/dL), serum creatinine concentration 
(0.92 ± 0.24 mg/dL), and estimated glomerular filtration 
rate (eGFR; 83.3  ±  21.8  mL/min/1.73  m2). In addition, 
white blood cell count ([WBC] not shown) was initially 
7.29 and finally 7.59  ×  10−3/µL, without appreciable 
change over years of lithium treatment.
The dose of lithium carbonate declined significantly 
over the years (0.78%/year) whereas serum lithium con-
centrations remained stable over time, reflecting dos-
ing adjustments as lithium clearance decreased with 
advancing age (Table  3). BMI increased slightly, from 
25.9 initially to a final mean value of 26.6 kg/m2, at a rate 
of 0.16%/year, and did not differ significantly between 
those given psychotropic drugs other than lithium or not 
(27.0 ±  5.36 vs. 26.3 ±  3.72 kg/m2; t =  1.36, p =  0.18). 
Serum glucose concentration also rose significantly over 
years of treatment and with advancing age, at 0.79%/year. 
BUN increased appreciably (from 23.7 to 33.1 mg/dL), at 
a rate of 1.4%/year, and creatinine rose at about half the 
rate of BUN, from 0.87 to 1.17 mg/dL, at 0.72%/year.
The metabolic measure of particular interest, eGFR, 
declined from a mean at intake of 94.2, to a final aver-
age of 62.2 mL/min/1.73 m2, at an average rate of decline 
of 0.915%/year (Table 3). Times to first-observed signifi-
cant increases in various measures vs. baseline included: 
BMI, just after the first year; glucose, from years 6–10; 
creatinine, years 16–20; and BUN, years 21–30. Decline 
of eGFR was noted starting from years 6–10, with a pro-
jected decline to the lower limit of normal (60 units) after 
30 or more years of exposure to lithium (Table 3).
Staging of renal deficiency
We considered changes in the prevalence of stages of 
renal function based on standard values (American 
National Kidney Foundation, NKF 2002, 2014) of eGFR, 
vs. years of lithium treatment (Fig. 1). The prevalence of 
normal or Stage I eGFR (≥90 mL/min/1.73 m2) declined 
over years of lithium exposure (and advancing age), from 
48.3% at intake to 9.80% after 31–48  years of exposure, 
whereas Stage 2 (60–89 units) declined slightly (from 
50.8 to 44.1% of subjects), and the prevalence of abnor-
mal eGFR Stages 3 and 4 eGFR (15–59 units) increased 
from 0.85 to 46.1%. No subject reached end-stage renal 
failure (Stage 5). The relative risk of each stage by sex 
(women/men) was: Stage 1, 0.72 (more in men); Stage 
2, 1.11; Stage 3, 1.68; and Stage 4, 9.29 (all three more 
in women); these sex-differences were highly significant 
(overall χ2 [df = 3] = 51.3, p < 0.0001).
Comparison of subjects with low vs. normal eGFR
A total of 92 (29.5%) of the 312 subjects had at least 
one estimate of eGFR below the lower limit of normal 
(<60  mL/min/1.73  m2). Based on the widely accepted 
criterion of ≥2 low values (Azab et al. 2015), the risk of 
eGFR  <  60 units was 18.1% [CI 13.9–22.7]. Character-
istics of subjects with vs. without low eGFR values were 
Table 3 Metabolic parameters in lithium-treated bipolar disorder patients
Data are based on means of N measurements (of a total of 2669) for 312 subjects over stated exposures to lithium treatment
Not shown are data for white blood cell counts (WBC), which did not change appreciably (initital: 7.29, final: 7.59 × 10–3 per µL)
BMI (body-mass index [kg/m2]), BUN (blood urea nitrogen [mg/dL]), creatinine [mg/dL], eGFR (estimated glomerular filtration rate for creatinine [mL/min/1.73 m2]), 
glucose (not necessarily fasting [mg/dL]), WBC (white blood cell count [thousands/µL])
a Values differ significantly from baseline measure, based on Tukey–Kramer post hoc tests comparing each exposure-interval to baseline values
Exposure 
(years)
N Lithium dose 
(mg/day)
Serum  [Li+] 
(mEq/L)
BMI (kg/m2) Glucose (mg/
dL)
BUN (mg/dL) Creatinine 
(mg/dL)
eGFR (mL/
min/1.73 m2)
Baseline 312 797 ± 283 0.594 ± 0.201 25.9 ± 4.81 88.1 ± 14.3 23.7 ± 11.4 0.87 ± 0.19 94.2 ± 23.3
1 312 859 ± 282 0.638 ± 0.171 27.9 ± 5.87a 90.5 ± 16.3 22.1 ± 10.4 0.86 ± 0.17 94.8 ± 22.2
2–5 1561 877 ± 296a 0.658 ± 0.185 27.3 ± 5.10a 90.9 ± 17.9 23.8 ± 10.8 0.87 ± 0.17 91.2 ± 21.1
6–10 1490 875 ± 310a 0.656 ± 0.177 27.5 ± 5.15a 97.4 ± 28.6a 24.5 ± 11.2 0.90 ± 0.19 86.1 ± 20.1a
11–15 1080 858 ± 320 0.672 ± 0.188 27.0 ± 4.57 95.3 ± 24.0a 25.4 ± 11.7 0.91 ± 0.21 83.9 ± 20.2a
16–20 739 815 ± 305 0.671 ± 0.191 27.6 ± 4.71a 98.6 ± 28.4a 26.9 ± 14.1 0.93 ± 0.24a 78.8 ± 19.3a
21–30 760 716 ± 289a 0.651 ± 0.172 27.6 ± 4.30a 103.8 ± 33.5a 31.2 ± 15.7a 0.98 ± 0.29a 72.7 ± 20.1a
≥31 201 647 ± 334a 0.607 ± 0.168 26.6 ± 5.03 121.9 ± 54.9a 33.1 ± 15.8a 1.17 ± 0.48a 62.2 ± 22.9a
Means [95% CI] 312 subjects 833 ± 311 
[824–842]
0.656 ± 0.184 
[0.650–0.662]
27.0 ± 4.86 
[26.5–27.5]
97.3 ± 28.4 
[94.1–100.5]
26.1 ± 12.9 
[24.7–27.5]
0.92 ± 0.24 
[0.89–0.95]
83.3 ± 21.8 
[80.9–85.7]
Change (%/
year)
2669 assays –0.777 [–0.654 
to –0.901]
–0.005 [–0.118 
to –0.118]
+0.162 
[0.011–0.311]
+0.787 
[0.619–0.954]
+1.41 
[1.10–1.72]
+0.724 
[0.609–0.839]
–0.915 [–0.822 
to –1.01]
p value 
[t‑score]
2669 assays <0.0001 [12.4] 0.94 [0.077] 0.04 [2.11] <0.0001 [9.21] <0.0001 [8.91] <0.0001 [12.4] <0.0001 [19.1]
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compared in initial bivariate comparisons (Tables  4, 5). 
Subjects with significantly lower eGFR were (a) more 
often women than men; (b) older at illness-onset, at 
starting lithium, and at final observation; (c) significantly 
less likely to be given co-treatments with anticonvulsants 
or antipsychotics; and (d) having significantly lower 
initial values of eGFR (Table  4). In addition, measures 
associated with low eGFR based on all assays, included 
(e) older at the time of assays; (f ) more likely to have 
medical comorbidities (mainly cardiovascular diseases, 
diabetes, hypercholesterolemia, hypertension, hypertri-
glyceridemia, hypothyroidism, or respiratory diseases); 
(g) longer exposure to lithium; (h) lower average doses 
of lithium carbonate; (i) without differences in mean 
serum lithium concentrations; (j) higher mean BUN; (k) 
higher serum glucose concentration; and (l) higher BMI 
(Table 5). Factors not associated with low eGFR included 
(a) diagnosis; (b) educational level; (c) metabolic syn-
drome; (d) abuse of alcohol or drugs; (e) cigarette smok-
ing; (f ) lifetime suicidal behavior, and (g) serum TSH 
levels.
Of note, antipsychotic drugs (59.2% of all subjects) 
were given with lithium more than either anticonvulsants 
(38.6%) or antidepressants (33.1%). Based on multiple 
variable logistic regression modeling, adjusted for age 
and sex (not shown), mood-altering anticonvulsants were 
associated with shorter exposure to lithium and lower 
serum concentrations. Use of antipsychotics was signifi-
cantly greater among subjects diagnosed with bipolar 
I than II disorder, as well as shorter exposure to lithium 
Fig. 1 Proportion (%) of subjects with Stages 1, 2, or 3 and 4 of renal 
function vs. years of lithium exposure. By linear regression, the preva‑
lence of Stage 1 renal function (normal) declined highly significantly 
(slope [β]: −1.12 [CI −1.36 to −0.88]; t = 10.6, p < 0.0001); Stage 2 
(mild dysfunction) remained stable (β: –0.035 [CI −0.373 to 0.303], 
t = 0.23, p = 0.82); and Stages 3 + 4 increased highly significantly (β: 
+1.15 [CI 0.91–1.40], t = 10.7, p < 0.0001)
Table 4 Factors associated with  vs. without  low eGFR 
among  312 bipolar disorder subjects treated long-term 
with lithium
Means are with 95% CI. Serum lithium concentration is in mEq/L; dose is of 
lithium carbonate is total mg/day. Additional factors not associated with low 
eGFR: (1) diagnosis (bipolar I vs. bipolar II), (2) education, (3) metabolic syndrome 
(overall risk = 30.4%), (4) any substance abuse, (5) alcohol abuse, (6) smoking, 
(7) any suicidal act, (8) serum TSH. Medical illnesses include cardiovascular and 
metabolic syndromes
a Low eGFR: subjects with at least one value <60 mL/min/1.73 m2; the observed 
rate of such subjects was 92/312 (29.5%), but 312/2669 assays (11.3%)
Factor Low  eGFRa Normal eGFR p-value [χ2 or 
t-score]
Subjects 92 220 –
Sex (%) 0.003 [8.98]
 Women 36.1 63.9
 Men 20.5 79.5
Ages (years)
 Illness onset 31.8 [29.4–34.2] 27.1 [25.7–28.5] 0.0007 [3.41]
 Started lithium 42.5 [39.8–45.2] 35.9 [34.2–37.6] <0.0001 [4.19]
 Final lithium 65.0 [62.4–67.6] 52.0 [50.3–53.7] <0.0001 [8.09]
Co‑treatments (%)
 Anticonvulsants 23.7 45.5 0.001 [10.4]
 Antipsychotics 47.4 64.6 0.01 [6.40]
 Antidepressants 25.0 36.1 0.07 [3.25]
Initial eGFR 77.2 ± 16.1 94.6 ± 21.9 <0.0001 [6.74]
Table 5 Measures associated with  vs. without  low eGFR 
among  2669 assays in  312 bipolar disorder subjects 
treated long-term with lithium
Means are with 95% CI. Serum lithium concentration is in mEq/L; dose is of 
lithium carbonate is total mg/day. Additional factors not associated with low 
eGFR: (1) diagnosis (bipolar I vs. bipolar II), (2) education, (3) metabolic syndrome 
(overall risk = 30.4%), (4) any substance abuse, (5) alcohol abuse, (6) smoking, 
(7) any suicidal act, (8) serum TSH. Medical illnesses include cardiovascular and 
metabolic syndromes
a Low eGFR: subjects with at least one value <60 mL/min/1.73 m2; the observed 
rate of such subjects was 92/312 (29.5%), but 312/2669 assays (11.3%)
b Most frequent medical comorbidities are: cardiovascular diseases, diabetes, 
hypercholesterolemia, hypertension, hypertriglyceridemia, hypothyroidism, and 
respiratory diseases
Measure Low  eGFRa Normal eGFR p-value [χ2 or 
t-score]
Age at assay 62.7 [61.4–64.0] 48.0 [47.5–48.5] <0.0001 [18.3]
Medical comor‑
bidity (%)b
83.5 59.5 <0.0001 [41.3]
Lithium exposure
 Years treated 19.6 [18.5–20.7] 11.2 [10.9–11.5] <0.0001 [16.3]
 Mean dose 588 [554–622] 884 [871–896] <0.0001 [15.5]
 Mean serum 
[Li+]
0.65 [0.63–0.68] 0.66 [0.65–0.67] 0.32 [0.99]
Physiological measures
 BUN 36.7 [34.3–39.1] 24.6 [24.0–25.2] <0.0001 [12.6]
 [Glucose] 108 [103–112] 95.8 [94.4–97.2] <0.0001 [5.88]
 BMI 28.5 [26.2–30.8] 26.4 [25.9–26.9] 0.03 [2.22]
Page 7 of 12Tondo et al. Int J Bipolar Disord  (2017) 5:27 
but at higher doses and serum concentrations. Antide-
pressants were given more often to bipolar II than bipolar 
I disorder subjects.
Declining eGFR with age and exposure to lithium
As expected, advancing age and years of lithium 
treatment were associated with low values for eGFR 
(<60  mL/min/1.73  m2), with corresponding increases 
in rates of elevated serum creatinine concentration 
(defined as  >1.2  mg/dL, based on the lower standard 
value for women rather than that of 1.5 mg/dL for men) 
(Fig.  2; Table  3). The rate of decline (slope function as 
%/year) averaged 0.710%/year of age, with a nonsignifi-
cantly steeper decline among women than men (0.756 
vs. 0.631%/year), and 0.915%/year of lithium exposure, 
with a significantly greater (non-overlapping CIs) rate 
of decline among women than men (0.934 vs. 0.785%/
year of lithium; Table  6). The overall observed rate of 
decline of eGFR was 28.9% greater for years of lithium 
treatment than for years of age (0.915 vs. 0.710%/year; 
Table 6).
For comparison with subjects not exposed to lithium, 
we obtained data from a study by Rule et al. (2004) who 
measured the effect of age in 365 healthy subjects on 
eGFR estimated as in the present study. These data indi-
cate a nonsignificantly lower rate of decline with age 
without than with lithium treatment (0.637 vs. 0.710%/
year), as well as a slightly larger decreases among women 
than men (Table  6). In addition, the rate of decline of 
eGFR was significantly greater with years of exposure 
Fig. 2 Values of eGFR (mL/min) [with 95% CI] among men and women: a vs. age; b vs. years of lithium treatment, pooled from 12 international 
sites, involving 2669 measurements among 312 bipolar disorder subjects treated with lithium for 8–44 years
Table 6 Rate of decrease of eGFR with age and lithium exposure (%/year)
Lithium-treated subjects are from the present study. Data for healthy adults are adapted from Rule et al. (2004) for clearance of iothalamate. Rates of GFR decrease 
as %/year are computed as [initial eGFR − observed eGFR]/[initial eGFR] × 100 with 95% confidence intervals and number (n) of subjects (eGFR is in units of mL/
min/1.73 m2)
Group eGFR decrease, %/year [95% CI] (n)
Age: healthy adults Age: lithium-treated Years of lithium
All subjects 0.637 [0.497–0.777] (365) 0.710 [0.653–0.767] (312) 0.915 [0.822–1.08] (312)
Men 0.488 [0.361–0.616] (160) 0.631 [0.545–0.717] (132) 0.785 [0.546–0.717] (132)
Women 0.754 [0.580–0.928] (205) 0.756 [0.682–0.829] (180) 0.934 [0.815–1.05] (180)
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to lithium (0.915%/year) than with age in subjects not 
exposed to lithium (0.637%/year; Table 6).
Renal effects of age at starting lithium treatment
Given the uncertain relative contributions of aging and 
exposure to lithium on declining eGFR, we considered 
a restricted sample of 610 assays, matched for long-
term treatment with lithium for 20–25  years (mean for 
both  =  22  years), but starting treatment at ages  <40 
vs.  ≥40  years (Table  7). Mean eGFR was highly sig-
nificantly lower among participants starting lithium at 
age ≥ 40 years. Moreover, risk of low values of eGFR was 
nearly twice as high (1.94-times) among the older sub-
jects, despite similar exposure to lithium.
Multivariable regression modeling
Finally, we carried out multivariable logistic regression 
modeling of factors associated with low eGFR (<60 mL/
min/1.73 m2). Factors remaining independently and sig-
nificantly associated ranked: (a) longer treatment with 
lithium, (b) lower mean daily dose of lithium carbonate, 
(c) higher mean serum lithium concentration, (d) older 
age at the time of assays, (e) co-occurring medical illness 
(Table 8). Not significantly associated with low eGFR in 
such modeling were sex, BMI, and co-treatment with an 
anticonvulsant, antipsychotic, or antidepressant drugs. 
Of note, serum concentration was associated with low 
eGFR only when adjusted for age, dose, and duration 
of exposure (Table  8), but not without such adjustment 
(Tables 4, 5).
Discussion
Among 312 adult bipolar disorder patients, treated for 
8–48  years with lithium carbonate (6142 person-years 
of exposure), from 12 international collaborating centers 
we found an incidence of low eGFR (<60 units) of 18.1% 
of subjects for ≥2 low values. The risk was 29.5% using 
a broad criterion of one low value, for which the overall 
female/male risk ratio was 1.76. Stage 1 eGFR (values 
of ≥90 units) was 39% more prevalent among men than 
women, whereas Stages 2 (60–89; by 11%), 3 (30–59; 
68%), and 4 (15–29 units, by 9.3-fold) were more fre-
quent among women. No subject reached end-stage renal 
dysfunction (ESRD), perhaps reflecting the source of 
study data from specialized mood-disorder clinics where 
close clinical follow-up would lead to suspension of treat-
ment before reaching ESRD. Close clinical monitoring 
probably is also reflected in the lack of decline in average 
serum concentrations of lithium over years of treatment, 
despite a significant decline in total daily dose, presum-
ably adjusted to maintain stable blood levels.
A particularly important finding is that eGFR declined 
with longer exposure to lithium treatment, but also with 
corresponding increases in age (Fig.  2; Table  6). Both 
factors were sustained as significant and independent 
in multivariable modeling (Table  8). Effects of aging on 
renal function are well established even among human 
subjects without known disease or toxic factors (Rule 
et al. 2004; Weinstein and Anderson 2010). Although we 
did not have a comparison sample of patients followed 
over time without lithium treatment, we could compare 
rates of decline of eGFR as a function of age and of time 
of exposure to lithium, and with reported rates of decline 
in healthy subjects (Rule et  al. 2004). Without lithium 
treatment, the rate of decline in eGFR (%/year) vs. age in 
normal subjects averaged 0.637 [CI 0.497–0.777] (Rule 
et  al. 2004), compared to 0.710 [0.653–0.767] for age in 
lithium-treated subjects, and to 0.915 [0.822–1.08] for 
years of lithium treatment (Table  6). These estimates 
are similar, with overlapping confidence intervals for the 
effect of aging, but a higher rate with lithium exposure. 
Additional reported data indicate a rate of decline of 
eGFR in healthy subjects of 0.708 [0.644–0.772]  %/year 
(American National Kidney Foundation, NKF 2014)—a 
value even closer to that found in our study for age 
among lithium-treated subjects. We also addressed the 
relative contributions to declining eGFR by considering 
a sample of subjects matched for long-term exposure to 
lithium (22 years), but starting the treatment at ages <40 
vs.  ≥40  years (Table  7). Mean eGFR was significantly 
higher among participants who started lithium at older 
ages, and the risk of low values of eGFR was nearly twice 
greater among the older subjects, despite similar expo-
sure to lithium. These findings indicate that effects of 
Table 7 Patients started on  lithium treatment below  or 
above age 40
Measure Age < 40 Age ≥ 40 p-value (t or χ2)
Subjects (n) 426 184 –
Years of lithium 22.3 ± 1.69 22.1 ± 1.63 0.123 (0.35)
Mean eGFR 77.6 ± 19.9 68.3 ± 17.9 <0.0001 (4.02)
eGFR < 60 units (%) 37.1 72.3 <0.0001 (63.8)
Table 8 Multivariate logistic regression model for  factors 
associated with low eGFR (<60 mL/min/1.73 m2)
Factor Odds ratio [95% CI] z-score p-value
Longer lithium treatment 
(years)
1.07 [1.04–1.09] 5.92 <0.0001
Lower mean lithium dose (mg/
day)
1.003 [1.002–1.004] 5.42 <0.0001
Higher mean serum  [Li+] 4.47 [4.36–43.5] 4.47 <0.0001
Older age at assay 1.04 [1.02–1.06] 4.32 <0.0001
Co‑occurring medical illness 2.11 [1.28–3.49] 2.91 0.004
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aging were greater than the exposure to lithium. Moreo-
ver, adverse effects of lithium on renal function may be 
greater at older ages.
The rate of decline of eGFR averaged 0.92% per year of 
lithium treatment, and was 19% higher among women 
than men. The observed overall rate of decline is consist-
ent with most (Bendz et  al. 1996, 2010; Bocchetta et  al. 
2013, 2015; Close et al. 2014; Aiff et al. 2015; Shine et al. 
2015; Kessing et  al. 2015; Hayes et  al. 2016), but not all 
(Clos et  al. 2015) retrospective reports on the effects of 
lithium on kidney function. In the study by Clos et  al. 
(2015), however, patients were exposed to lithium for 
an average of 55  months, possibly too brief to support 
detection of effects on kidney function (Davis et al. 2015; 
Bocchetta et  al. 2016). Interestingly, however, a similar 
lack of effect of lithium on renal function was found in 
a 4-years prospective study in elderly patients with mild 
cognitive impairment (Aprahamian et  al. 2014). In the 
present findings, average values of eGFR became signifi-
cantly lower than baseline levels by 6–10 years of treat-
ment, and a mean decline to the lower limit of normal 
(60 units) required  ≥30  years of exposure to lithium 
(Table 3). Other reports of long-term lithium treatment 
effects on renal function are consistent with this observa-
tion (Bendz et al. 2010; Bocchetta et al. 2015; Shine et al. 
2015). We also found that risk of later low values of eGFR 
were strongly predicted by lower initial values (Table 4). 
Exposure to lithium treatment needed to be at least 
6–10 years to be associated with significant decreases of 
eGFR (Table 3).
Our finding of greater risk of a decline in eGFR among 
women is also consistent with some recent reports (Boc-
chetta et al. 2015; Shine et al. 2015) suggesting a higher 
vulnerability of women to developing lithium-related 
effects on kidney. Of note, however, other studies have 
found greater risk of declining eGFR among men (Ryba-
kowski et al. 2012; Bocchetta et al. 2013) or no sex differ-
ence (Aiff et al. 2015).
Serum concentrations of urea (BUN) increased by 
1.41%/year, glucose by 0.787%/year, and creatinine by 
0.724%/year—all rising with longer exposure to lith-
ium and correspondingly advancing age. The observed 
increase in serum glucose levels contrasts with a study 
reporting a nonsignificant increase in glucose levels after 
four years of treatment with lithium in elderly patients 
(Aprahamian et al. 2014). Interestingly, studies in animals 
evaluating the effects of lithium on glucose metabolism 
also may be discordant with our findings (Shah and Pish-
dad 1980; Tabata et al. 1994). Indeed, whereas Shah and 
Pishdad (1980) found that lithium induced the hyper-
glycemia in rats, Tabata et  al. (1994) found a markedly 
increased sensitivity of glucose transport to insulin after 
lithium treatment.
We also found that average BMI increased by 0.162%/
year of treatment with lithium, with a significant increase 
over baseline values by the end of the first year of expo-
sure, but little more thereafter (Table  3). This finding 
confirms that lithium may contribute to weight gain 
(Mathew et  al. 1989; Atmaca et  al. 2002), although the 
effect might reflect exposure to other weight-increasing 
agents including antipsychotic drugs (Calkin et al. 2009). 
However, the potential adverse risks associated with 
long-term treatment with lithium need to be balanced 
against major clinical benefits of treatment with lithium 
(McKnight et al. 2012; Severus and Bauer 2013; Kessing 
et al. 2015).
Several factors were associated with loss of eGFR dur-
ing long-term treatment with lithium (Tables  4, 5, 6, 7 
and 8). Notably, declining eGFR was associated with 
serum lithium concentrations only when adjusted for 
age, dose of lithium, and duration of lithium exposure, 
whereas total daily doses of lithium carbonate were actu-
ally lower with low eGFR, in association with older age 
(Tables 4, 5, and 8). These findings suggest that dose was 
adjusted to maintain therapeutic serum levels in the face 
of declining renal clearance of lithium and with age. We 
also found that medical comorbidities (especially dia-
betes and hypertension) were associated with declining 
eGFR. In contrast, use of adjunctive treatments, espe-
cially modern antipsychotic drugs and mood-altering 
anticonvulsants, were associated with less risk of low 
eGFR values (Tables  4, 5). These associations are not 
readily explained. Patients with low eGFR were older, had 
more general medical comorbidity, and were given fewer 
psychotropic drugs of all kinds as well as lower doses of 
lithium. Of note, there is suggestive evidence that anti-
convulsants and antipsychotics may themselves contrib-
ute to risk of renal damage (Hwang et  al. 2014; Kessing 
et  al. 2015). Other findings implicate episodes of acute 
lithium intoxication (possibly an indication of more 
aggressive treatment) with declining renal function (Rej 
et al. 2012).
There may be effects of once-daily vs. multiple daily 
dosing with lithium on renal function (Carter et  al. 
2013; Castro et  al. 2016). Some evidence suggests less 
renal toxicity with once-daily dosing, but the findings 
are inconsistent, and may be confounded by likely use 
of lower doses with once-daily regimens (Schou et  al. 
1982; Carter et al. 2013). Moreover, the observed effects 
pertain mainly to small reductions in 24-h urine vol-
ume (Kusalic and Engelsmann 1996). Once-daily dos-
ing is perhaps best reserved for young, vigorous patients 
given moderate doses of lithium to limit the potentially 
toxic impact of high, daily peak serum concentrations. 
Reducing lithium dose might be expected to limit toxic 
effects as was supported by present findings (Tables 4, 5, 
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assuming that dose was not lowered because of declin-
ing renal function). Lithium dose can be reduced by use 
of combinations with other agents with mood-stabilizing 
effects, including some anticonvulsants or antipsychotics.
Consideration of these factors during appropriately 
close, long-term clinical monitoring should help to limit 
risks of renal impairment with long-term lithium treat-
ment  (Paul et  al. 2010). In addition, there may be bene-
fits in monitoring serum concentrations of lithium levels 
relatively frequently, especially in elderly patients. It has 
been suggested that lithium levels should be monitored 
every 3 months since even a single occurrence of a level 
higher than 1.0  mEq/L may result in a modest but sig-
nificant decrease of the GFR lasting for at least 3 months 
(Bauer et al. 2006; Van Beneden et al. 2011; Kirkham et al. 
2014; Davis et al. 2015; Shine et al. 2015). In general, we 
would emphasize the importance of appropriate selection 
of patients for long-term lithium treatment, maintaining 
them on minimum effective doses and daily trough serum 
concentrations especially for older populations, and reg-
ular monitoring to assess adherence to prescribed treat-
ment. These principles of safe practice are important to 
emphasize, especially as many mood-disorder patients are 
followed by primary-care clinicians and are not followed 
in specialized programs directed by experts (Müller-Oer-
linghausen et al. 2012).
Limitations
The present findings should be interpreted in the context 
of some limitations. First, the study is retrospective in 
nature. However, clinical data were collected longitudi-
nally in specialized mood-disorder clinics where patients 
are followed up systematically and at regular intervals, 
increasing the statistical accuracy of gathered informa-
tion. Second, the main measure of renal function in this 
study was estimated GFR based on serum concentra-
tions of creatinine, and not on independently verified 
clearance of an exogenous test molecule. The formulas 
employed may not adequately reflect the rate of glomeru-
lar filtration at very high concentrations of creatinine, 
such as  >1.75  mg/dL (Levey et  al. 2009; Stevens 2013). 
Nevertheless, eGFR is widely employed measure of renal 
function and is readily obtained for routine clinical use. 
Finally, we lacked a comparison group without lithium 
treatment, leaving the important question of effects of 
aging vs. of lithium on eGFR unresolved.
Conclusions
This multisite, international, long-term study found sig-
nificant changes in renal function and other metabolic 
measures in association with very prolonged treatment 
with lithium carbonate given to prevent recurrences 
of bipolar disorder. It adds to evidence that long-term 
lithium treatment is associated with a decline in renal 
function as expressed by significant decreases of eGFR 
over time. We found moderate decreases in eGFR after 
prolonged exposure to lithium (at least 6–10 years) and 
advancing age, along with increases in serum creatinine 
and BUN concentrations, and small increases in glucose 
levels and BMI. No cases of severe or end-stage renal 
failure were encountered, probably owing to close clini-
cal monitoring and timely interventions in cases with 
declining renal function. We found greater decreases in 
eGFR among women than men, and following lower ini-
tial values of eGFR, as well as when lithium treatment 
was started at older ages. The study findings contribute to 
clarifying relationships between long-term lithium treat-
ment and its metabolic safety profile. Overall, this study 
and those summarized above (Table  1) indicate, with 
some notable inconsistencies, that there were major risks 
of declining eGFR with very prolonged treatment with 
lithium salts, but that effects of advancing age also are 
prominent and confound quantification of risk-by-time 
specific to lithium exposure. Noteworthy risk factors 
for low eGFR included female sex, higher serum lithium 
level, longer lithium treatment, lower initial eGFR, and 
medical comorbidity, as well as older age. A clinically 
favorable conclusion is that emerging decreases in renal 
function can be detected readily with regular metabolic 
monitoring, and probably modified by timely interven-
tions that include an increasing number of apparently 
effective treatment options to lithium.
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